Shares of NanoViricides surged 10.7% to $1.16 on September 15, bucking a 2.11% decline in the broader biotech sector, after the company announced it expects to dose its first Ebola patient next week in the Democratic Republic of Congo. The adaptive Phase IIA/IIB trial will evaluate an oral antiviral gummy as a treatment for Bundibugyo ebolavirus at an Ebola Treatment Center in Ituri province, initially assessing safety and dosing before moving to a randomized efficacy evaluation. For a company worth roughly $29 million with zero revenue, the stakes are enormous — and so is the risk.
The Outbreak Creates Urgent Demand — and a Regulatory Fast Lane. As of September 14, the DRC has reported 7,258 confirmed Ebola cases and 3,510 deaths.
There is no approved vaccine or treatment for the Bundibugyo virus — existing therapies like Regeneron's Inmazeb were designed for a different Ebola strain (Zaire). By early August, this had become the fastest-growing Ebola outbreak on record, complicated by the fact that existing treatments target a different strain. That vacuum is exactly why a tiny firm got DRC regulatory clearance in weeks, not years.
An Oral Drug Could Be a Game-Changer in Remote Settings — If It Works. NanoViricides claims its drug is the only orally active agent under consideration for clinical trial as a treatment of Ebola. Competing therapies require IV infusions — impractical in conflict-ridden eastern Congo. The company believes "an oral drug is a highly advantageous feature" in resource-limited epidemic scenarios. A chewable gummy that can be distributed without needles or refrigeration would represent a meaningful advance, but Phase II trials fail more often than they succeed.
The Cash Runway Tells a Sobering Story. NanoViricides holds just $3.21 million in cash and no debt.
Over the last 12 months, it burned $7.37 million in free cash flow — meaning at current burn rates, the company has roughly five months of funding left. Shares outstanding have already increased 32.11% over the past year , signaling dilution — where the company issues new stock to raise money, shrinking existing investors' ownership. More fundraising is almost certain.
A Phase II Start Is Not a Finish Line. The stock's pop reflects hope, not proof. Even a successful Phase II would leave NanoViricides years and hundreds of millions away from commercialization. The global Ebola treatment market is estimated at just $188 million in 2026 — a small prize. With earnings due September 28, investors will soon see whether the burn rate has accelerated. For now, NNVC is a lottery ticket tied to a humanitarian crisis.